The fact that HDAC and PI3K inhibitors had been approved by the FDA for treatment of hematologic cancers encouraged us to test the antiproliferative activity of compound 23 against hematologic tumor cells. The gene discussed is HDAC9; the disease is hematopoietic and lymphoid cell neoplasm.